Issuu

RESOURCE CENTER

www.ExchangeCME.com/ ACTIVATEPrEPResources

This activity is provided by Integritas Communications. (ACCME Credit) This activity is jointly provided by Global Education Group (Global) and Integritas Communications. (ANCC Credit) This activity is supported by an educational grant from Gilead Sciences, Inc. This program was developed by, or with financial support and influence from, Integritas Communications and is neither sponsored by nor endorsed by ATS.

RESOURCE CENTER

PREAMBLE

FACULTY

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

CME/MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com 2

FACULTY FACULTY

Gregory “Grey” Felzien, MD, AAHIVS Diplomat: Internal Medicine & Infectious Disease Medical Codirector Positive Impact Health Centers Atlanta, Georgia

Jason Halperin, MD, MPH, FIDSA Director of Specialty Services DAP Health & Borrego Health Palm Springs, California

Stacey B. Trooskin, MD, PhD, MPH Executive Medical Officer Medical and Behavioral Health Programs Mazzoni Center Philadelphia, Pennsylvania

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

PROGRAM DESCRIPTION

PREAMBLE

ACTIVATE PrEP is a CME/CE meeting series designed to help clinics who are already prescribing preexposure prophylaxis (PrEP) to optimize same-day and rapid initiation workflows. Many community health centers and sexual health clinics have the intent and infrastructure to offer immediate PrEP initiation but face persistent challenges that impede consistent implementation, including workflow inefficiencies, limited staff capacity, pharmacy coordination, and reimbursement uncertainty. Expert faculty will engage interprofessional care teams through a one-hour customized in-clinic learning session, assessing site-specific barriers, reviewing best practices, and developing actionable plans to improve timeliness and equity in PrEP delivery. Structured follow-up consultations will support progress toward defined implementation goals, ensuring measurable and sustainable workflow change. Educational resources and community outreach tools/support will further extend impact.

TARGET AUDIENCE The educational design of this activity addresses the needs of community-based clinicians providing HIV prevention care, including primary care, OB/GYN, pharmacy, addiction medicine, and urgent care professionals (physicians, NPs, PAs, nurses, and pharmacists).

EDUCATIONAL OBJECTIVES Upon completion of this activity, participants will be better prepared to: • Implement guideline-aligned same-day/rapid PrEP initiation workflows, including eligibility, testing, and prescribing • Diagnose and optimize site-specific barriers (order sets, standing orders, staffing, and access pathways) • Integrate patient-centered counseling strategies that reduce stigma and support uptake/adherence • Define clinic pathways to offer long-acting PrEP when clinically appropriate and operationally feasible • Develop and track a site-specific action plan with roles, milestones, and sustainability considerations

PHYSICIAN ACCREDITATION STATEMENT Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

JOINT ACCREDITATION STATEMENT In support of improving patient care, this activity has been planned and implemented by Global Education Group and Integritas Communications. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Global Education Group designates this continuing education activity for 1.0 contact hour including 0.0 pharmacotherapeutic contact hour.

INSTRUCTIONS TO RECEIVE CREDIT In order to receive credit for this activity, the participant must complete the pretest, posttest, and evaluation form.

INTEGRITAS CONTACT INFORMATION For information about the accreditation (ACCME credit) of this program, please contact Integritas at info@exchangecme.com.

GLOBAL CONTACT INFORMATION For information about the joint accreditation (ANCC credit) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

FEE INFORMATION& REFUND/CANCELLATION POLICY There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS Integritas Communications and Global adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated

PREAMBLE

NURSING CONTACT HOURS DESIGNATION

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies: Gregory “Grey” Felzien, MD, AAHIVS

Nothing to disclose

Jason Halperin, MD, MPH, FIDSA

Nothing to disclose

Stacey B. Trooskin, MD, PhD, MPH

Nothing to disclose

PREAMBLE

The planners and managers at Integritas Communications and Global Education Group have no relevant financial relationships to disclose. The following planners and managers have no relevant financial relationships with ineligible companies to disclose: Rhys Williams, RN, MSN, FNP (Nurse Planner)

DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SLIDES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

CLINICAL PRACTICE GUIDELINES Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. US Public Health Service. Centers for Disease Control and Prevention; 2021. » https://stacks.cdc.gov/view/cdc/112360

Final Recommendation Statement. Prevention of Acquisition of HIV: Preexposure Prophylaxis. U.S. Preventive Services Task Force. 2023. » https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prevention-of-humanimmunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis

Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. Gandhi RT, et al. JAMA. 2025;333(7):609-628. » https://pubmed.ncbi.nlm.nih.gov/39616604/

Preexposure prophylaxis for HIV: updated recommendations from the 2024 International Antiviral Society-USA Panel. Landovitz RJ, et al. JAMA. 2025. Epub ahead of print. » https://pubmed.ncbi.nlm.nih.gov/40576995/

Sexually transmitted infections treatment guidelines. 2021. Centers for Disease Control and Prevention. Last reviewed July 2021. » https://www.cdc.gov/std/treatment-guidelines/default.htm

CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. Bachmann LH, et al. MMWR Recomm Rep. 2024;73(2);1-8.

RESOURCE CENTER

» https://pubmed.ncbi.nlm.nih.gov/38833414/

2018 quick reference guide: recommended laboratory HIV testing algorithm for serum or plasma specimens. CDC Stacks. Centers for Disease Control and Prevention; last updated January 2018. » https://stacks.cdc.gov/view/cdc/50872

Antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV - CDC recommendations, United States, 2025. Tanner MR, et al. MMWR Recomm Rep. 2025;74(1):1-56. » https://pubmed.ncbi.nlm.nih.gov/40331832/

The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health. Makadon H, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015. » https://www.lgbtqiahealtheducation.org/publication/textbook/

National Institute of Allergy and Infectious Diseases HIV Language Guide, 2024. » https://www.prepwatch.org/resources/niaid-hiv-language-guide-2024/

PROFESSIONAL ORGANIZATIONS & RESOURCES HealthHIV. HIV PrEP Navigation Certification Program™. » https://healthhiv.org/hivpnc/

American Academy of HIV Medicine. » https://aahivm.org/

HIV Nexus: CDC Resources for Clinicians. Centers for Disease Control and Prevention. » https://www.cdc.gov/hivnexus/hcp/index.html

National Clinician Consultation Center. University of California, San Francisco; 2023. » https://nccc.ucsf.edu/

HIV drug interactions. University of Liverpool (website). » http://www.hiv-druginteractions.org/checker

HIV Public Health Partners: State HIV Prevention Profiles. Centers for Disease Control and Prevention. » https://www.cdc.gov/hivpartners/php/state-hiv-profiles/

State Laws and Policies: Minors’ Access to STI Services; updated March 2025. Guttmacher.

RESOURCE CENTER

» https://www.guttmacher.org/state-policy/explore/minors-access-sti-services

PrEP implementation checklists. PrEPWatch. » www.prepwatch.org/wp-content/uploads/2024/03/PrEP-Gain-framing-Checklist-Eng.pdf

Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), and Other HIV Prevention Strategies Billing and Coding Guide; October 2023. NASTAD. » https://nastad.org/sites/default/files/2023-10/PDF-HIV-Prevention-BillingAndCoding-101223.pdf

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

SUGGESTED READING Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. Baeten JM, et al. N Engl J Med. 2012;367(5):399-410. » http://www.nejm.org/doi/full/10.1056/NEJMoa1108524#t=article

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Choopanya K, et al. Lancet. 2013;381(9883):2083-2090. » http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61127-7/abstract

Emtricitabine/tenofovir alafenamide. HIV.gov. Drug database. » https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-alafenamide/fda-label

Emtricitabine/tenofovir disoproxil fumarate. HIV.gov. Drug database. » https://clinicalinfo.hiv.gov/en/drugs/emtricitabine-tenofovir-disoproxil-fumarate/fda-label

Cabotegravir. HIV.gov. Drug database. » https://clinicalinfo.hiv.gov/en/drugs/cabotegravir-1/fda-label

Lenacapavir. HIV.gov. Drug database. » https://clinicalinfo.hiv.gov/en/drugs/lenacapavir/fda-label

Being PrEPared—preexposure prophylaxis and HIV disparities. Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295. » https://www.nejm.org/doi/full/10.1056/NEJMp1804306

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599. » http://www.nejm.org/doi/full/10.1056/NEJMoa1011205#t=article

RESOURCE CENTER

Lifetime risk of a diagnosis of HIV infection in the United States. Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243. » https://www.sciencedirect.com/science/article/abs/pii/S1047279717301539?via%3Dihub

Cabotegravir for HIV prevention in cisgender men and transgender women. Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608. » https://www.nejm.org/doi/full/10.1056/NEJMoa2101016

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Delany-Moretlwe S, et al. Lancet. 2022;399(10337):1779-1789. » https://pubmed.ncbi.nlm.nih.gov/35378077/

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Mayer KH, et al. Lancet. 2020;396(10246):239-254. » https://pubmed.ncbi.nlm.nih.gov/32711800/

Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. Bekker, et al. N Engl J Med. 2024;391(13):1179-1192. » https://pubmed.ncbi.nlm.nih.gov/39046157/

Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276. » https://pubmed.ncbi.nlm.nih.gov/39602624/

PrEP ACCESS, ASSISTANCE, AND INFORMATION Patient and Provider assistance: PleasePrEPMe.org. Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state » https://pleaseprepme.org/

Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center Supports national HIV priorities by providing training, consultation, and resources » https://aidsetc.org/

Patient assistance (without insurance). The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines.

RESOURCE CENTER

» https://www.gilead.com/purpose/medication-access/us-patient-access

Uninsured 24/7 support online, by phone during business hours and fax enrollment. » https://www.gileadadvancingaccess.com/financial-support/uninsured

Copay assistance (for patients with nongovernment insurance). » https://www.gileadadvancingaccess.com/copay-coupon-card » Phone number: 1-800-226-2056

Copay assistance/out-of-pocket costs. ViiV Connect. » https://www.viivconnect.com/hcp/get-financial-support/

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

NOTES

Adopting Clinic Transformation for Immediate, Viable, and Timely Execution

NOTES

Subscribe to our YouTube channel @exchangecme for additional informative videos.

youtube.com/c/ExchangeCME

GET FREE ACCESS TO THE LATEST CME/CE ACTIVITIES, WEBINARS, EVENTS, AND MORE! Answers to Everyday Challenges in PrEP Practice A Phone-a-Friend Peer Consult Series ExchangeCME.com/groups/PrEPPhoneAFriend

Shining a Light

On the PCP’s Role in HIV Prevention ExchangeCME.com/2025PrEPforPCPs

Covering the Span of Primary Care Educational Needs in PrEP Implementation

Multi-Media eHealth Activities for Treaters New To and Experienced With PrEP Provision Scan the QR code or visit this URL to download the activity booklets. ExchangeCME.com/PrEPeHealthCRC

CHECK US OUT ON YOUT UB

ExchangeCME.com is the fastest-growing digital platform for accredited CME/CE and MOC programming. Join the movement of thousands of health care professionals and make sure you stay up to date on best practices to manage your patients!

Free accredited online

activities with immedia te access to your certifi cates Live in-person and onlin e events

Clinical Resource Center s on Live streaming of sympo Tailored e-newsletters

various therapeutic area

sia at major medical co nferences

based on your interest

Subscribe to our YouTube channel @exchangecme for additional informative videos.

youtube.com/c/ExchangeCME

For additional program information and resources, please visit the CLINICAL RESOURCE CENTER

www.ExchangeCME.com/ ACTIVATEPrEPResources

© 2026 Integritas Communications. All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.